FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W128260107> ?p ?o ?g. }

• W128260107 abstract "Objective: LCZ696 is a first-in-class angiotensin receptor neprlysin inhibitor (ARNI) being developed for the treatment of hypertension and heart failure. Ingestion of LCZ696 results in systemic exposure to AHU377 (inactive prodrug of LBQ657, a neprilysin inhibitor) and valsartan (angiotensin receptor blocker). Carvedilol is a third-generation, non-selective beta-blocker with vasodilating properties and one of three beta-blockers with efficacy in reducing the risk of death in patients with heart failure. Since LCZ696 may be co-administered with carvedilol for optimal blood pressure control, this study was conducted to evaluate the pharmacokinetic (PK) drug-drug interaction potential between LCZ696 and carvedilol. Methods: An open-label, three-period, single sequence study in 28 healthy subjects was conducted. In Period 1, subjects received oral LCZ696 400 mg qd x 5 days and were discharged for a 4-10 day washout. In Period 2, subjects received oral carvedilol 12.5 mg bid x first 2 days, then 25 mg bid x 4 days, and in Period 3, LCZ696 400 mg qd + carvedilol 25 mg bid x 5 days. Serial PK samples were collected and analyzed by a validated LC-MS/MS method. PK parameters (AUCtau,ss, Cmax,ss) of LCZ696 analytes(LBQ657, valsartan) and carvedilol (R(+)-and S(-)-carvedilol) in plasma were determined using non-compartmental analysis, and results were statistically evaluated. Results: The 90% CIs of the geometric mean ratio for AUCtau,ss and Cmax,ss of LBQ657, and AUCtau,ss of valsartan fell within the range of (0.80-1.25); the lower bound for Cmax,ss of valsartan (0.88, 0.78-0.98) was below the range, indicating PK of LBQ567 was not altered but Cmax,ss of valsartan decreased by 12% when co-administered with carvedilol. Those for AUCtau,ss and Cmax,ss of both R(+)-and S(-)carvedilol fell within the range (0.80-1.25), indicating no change in PK of Carvedilol in combination with LCZ696. Conclusion: When LCZ696 400 mg qd and carvedilol 25 mg bid were co-dministered, PK of carvedilol (R(+)-and S(-)-carvedilol) was unchanged. PK of LBQ657 or AUCtau,ss of valsartan was unchanged, while Cmax,ss decreased by 12%. LCZ696 400 mg qd was safe and well tolerated in healthy subjects when administered alone and in combination with carvedilol 25 mg bid." @default.
• W128260107 created "2016-06-24" @default.
• W128260107 creator A5005175187 @default.
• W128260107 creator A5031520819 @default.
• W128260107 creator A5036792690 @default.
• W128260107 creator A5073730931 @default.
• W128260107 creator A5082018881 @default.
• W128260107 creator A5083156364 @default.
• W128260107 date "2013-09-01" @default.
• W128260107 modified "2023-09-25" @default.
• W128260107 title "Abstract 457: Assessment of Pharmacokinetic Drug-drug Interaction between LCZ696 and Carvedilol" @default.
• W128260107 doi "https://doi.org/10.1161/hyp.62.suppl_1.a457" @default.
• W128260107 hasPublicationYear "2013" @default.
• W128260107 type Work @default.
• W128260107 sameAs 128260107 @default.
• W128260107 citedByCount "1" @default.
• W128260107 countsByYear W1282601072015 @default.
• W128260107 crossrefType "journal-article" @default.
• W128260107 hasAuthorship W128260107A5005175187 @default.
• W128260107 hasAuthorship W128260107A5031520819 @default.
• W128260107 hasAuthorship W128260107A5036792690 @default.
• W128260107 hasAuthorship W128260107A5073730931 @default.
• W128260107 hasAuthorship W128260107A5082018881 @default.
• W128260107 hasAuthorship W128260107A5083156364 @default.
• W128260107 hasConcept C112705442 @default.
• W128260107 hasConcept C126322002 @default.
• W128260107 hasConcept C2778198053 @default.
• W128260107 hasConcept C2780035454 @default.
• W128260107 hasConcept C2780591200 @default.
• W128260107 hasConcept C2910466267 @default.
• W128260107 hasConcept C71924100 @default.
• W128260107 hasConcept C98274493 @default.
• W128260107 hasConceptScore W128260107C112705442 @default.
• W128260107 hasConceptScore W128260107C126322002 @default.
• W128260107 hasConceptScore W128260107C2778198053 @default.
• W128260107 hasConceptScore W128260107C2780035454 @default.
• W128260107 hasConceptScore W128260107C2780591200 @default.
• W128260107 hasConceptScore W128260107C2910466267 @default.
• W128260107 hasConceptScore W128260107C71924100 @default.
• W128260107 hasConceptScore W128260107C98274493 @default.
• W128260107 hasLocation W1282601071 @default.
• W128260107 hasOpenAccess W128260107 @default.
• W128260107 hasPrimaryLocation W1282601071 @default.
• W128260107 hasRelatedWork W2033565322 @default.
• W128260107 hasRelatedWork W2048283300 @default.
• W128260107 hasRelatedWork W2105520237 @default.
• W128260107 hasRelatedWork W2119268070 @default.
• W128260107 hasRelatedWork W2165831607 @default.
• W128260107 hasRelatedWork W2323406916 @default.
• W128260107 hasRelatedWork W2329711784 @default.
• W128260107 hasRelatedWork W2338387536 @default.
• W128260107 hasRelatedWork W2442729409 @default.
• W128260107 hasRelatedWork W2520443047 @default.
• W128260107 hasRelatedWork W2550655292 @default.
• W128260107 hasRelatedWork W2757647121 @default.
• W128260107 hasRelatedWork W2894581108 @default.
• W128260107 hasRelatedWork W2899010506 @default.
• W128260107 hasRelatedWork W2919463403 @default.
• W128260107 hasRelatedWork W2997153768 @default.
• W128260107 hasRelatedWork W2999392516 @default.
• W128260107 hasRelatedWork W3030980818 @default.
• W128260107 hasRelatedWork W3032419305 @default.
• W128260107 hasRelatedWork W3032431997 @default.
• W128260107 isParatext "false" @default.
• W128260107 isRetracted "false" @default.
• W128260107 magId "128260107" @default.
• W128260107 workType "article" @default.